Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
Altundag
Ozden
O
Altundag
Kadri
K
Silay
Kamile
K
Turen
Selahattin
S
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000453:epidemiology; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D017678:Sex Distribution; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil